ISoP New Board of Trustees Members Announced
November 08 2023 - 8:30AM
Business Wire
Amparo de la Peña, Vice President of
Pharmacometrics at Simulations Plus, will join Jeff Sachs, Pavan
Vaddady and Hao Zhu as new board members for 2024
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical and
biotechnology industries, announced today that Amparo de la Peña,
Vice President of Pharmacometrics, has been elected to the
International Society of Pharmacometrics (ISoP) Board of
Trustees.
“Amparo is an experienced pharmacometrician, having spent more
than 20 years working for Eli Lilly and Company before going into
consulting and serving small biotechs and big pharma companies in
diverse therapeutic areas. Throughout her career, she has always
sought ways to volunteer and support the growth of our discipline
and the careers of junior scientists just starting out,” said Jill
Fiedler-Kelly, President of Clinical Pharmacology &
Pharmacometrics at Simulations Plus. “In this leadership role, I
know Amparo will help extend the influence and impact of ISoP
throughout our global industry.”
Three other Trustees were elected to the Board: Jeff Sachs, a
Distinguished Scientist at Merck; Pavan Vaddady, Sr. Director &
Head of Pharmacometrics, Quantitative Clinical Pharmacology at
Daiichi Sankyo, Inc.; and Hao Zhu, Division Director of
Pharmacometrics, Office of Clinical Pharmacology at FDA.
“We were fortunate to have so many distinguished candidates
whose visionary ideas about how to grow ISoP were inspiring,” said
Jennifer Pastore Monroy, Executive Director of ISoP. “We are
excited for the energy, enthusiasm, and perspectives [our new
Trustees] will bring to the Board.”
The newly elected Trustees will assume their roles effective
January 1, 2024.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
www.simulations-plus.com. Follow us on LinkedIn | Twitter |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2022 ESG update.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108328896/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Tamara Gonzalez
310-622-8234 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2024 to May 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From May 2023 to May 2024